Stephen Liu, Chief of the Division of Hematology and Oncology, and Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared on X:
“Report from JTO describes mechanisms of acquired resistance to 1L lazertinib in EGFR mutant NSCLC from phase 3 LASER301 trial. Overall, 59% had an acquired alteration and of those, 58% were complex (≥ alterations). 16% on target EGFR dependent resistance (9% EGFR C797S). 43% EGFR independent including HER2 and MET alterations (10% each). EGFR amplification at baseline significantly associated with shorter PFS. ctDNA clearance achieved by most (94%) of patients.”
Title: Mechanisms of Acquired Resistance and ctDNA Clearance in EGFR-Mutated Advanced NSCLC Following Lazertinib Treatment: Results From the Phase 3 LASER301 Study
Authors: Myung-Ju Ahn, Ki Hyeong Lee, Chin Heng Fong, Anastasia Zimina, Yong Kek Pang, Sergey Orlov, Sun Min Lim, Jong-Mu Sun, Jason K. Sa, Jisoo Hong, YuKyung Kim, Mi-Jung Kwon, SeokYoung Choi, Dongmin Kim, Min Kim, Byoung Chul Cho.
You can also read ‘MARIPOSA: Amivantamab Plus Lazertinib Reduces EGFR/MET Resistance and Extends Second-Line Disease Control in EGFR-Mutated NSCLC‘
